FCGR3A and B-cell chronic lymphocytic leukemia: Recent studies showed that patients with follicular lymphoma, Waldenström’s macroglobulinemia, and chronic lymphocytic leukemia responded to rituximab treatment at different rates due to FcγRIIIA gene SNPs [13,14,15,16].